Anthera Pharma (ANTH) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Anthera Pharmaceuticals Provides Business Update and Reports 2016 First Quarter Financial Results
May 9, 2016 8:38 AM EDTSOLUTION clinical study of Sollpura expanded to Europe, Israel and Canada in addition to ongoing US enrollmentCraig Thompson named as President and Chief Operating OfficerAppointment of Dr. James Pennington to Interim Chief Medical OfficerEnrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completedBulk manufacturing campaign for blisibimod completed for CHABLIS-7.5
HAYWARD, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the first quarter ended March 31, 2016.
Recent Developments and Business Highlights:
Sollpura (liprotamase)... More
